Valeant Pharmaceuticals (VRX) PT Lowered to $18 at RBC Capital Ahead of Q3 Print; Says FY18 Cons. 'Too High'
Tweet Send to a Friend
RBC Capital analyst Douglas Miehm lowered his price target on Valeant Pharmaceuticals (NYSE: VRX) to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
